Get startedLog in
    Picture of Novo Nordisk A/S logo

    NVO — Novo Nordisk A/S News Story

    0.000.00%
    us flag iconLast trade - 00:00
    HealthcareAdventurousLarge CapSuper Stock
    All News

    Brief: Novo And Hengrui Pharma Enter Exclusive License Agreement For HRS-1596

    Picture of Novo Nordisk A/S logoNovo Nordisk A/S
    29/09/2026 05:43
    BRIEF-Novo And Hengrui Pharma Enter Exclusive License Agreement For HRS-1596
    Sept 29 (Reuters) - Novo Nordisk A/S NOVOb.CO:
    • NOVO AND HENGRUI PHARMA ENTER EXCLUSIVE LICENSE AGREEMENT FOR ONCE-WEEKLY ORAL GLP-1/GIP DUAL RECEPTOR AGONIST HRS-1596
    • NOVO NORDISK - DEAL VALUE UP TO $2.60 BILLION INCLUDING $300 MILLION UPFRONT AND SALES ROYALTIES
    • NOVO NORDISK - OBTAINS EXCLUSIVE GLOBAL RIGHTS TO HRS-1596 EXCLUDING CHINA, HONG KONG, MACAO, TAIWAN
    • NOVO NORDISK - HENGRUI PHARMA APPROVED TO INITIATE PHASE 1 TRIALS WITH HRS-1596 IN CHINA
    • NOVO AND HENGRUI PHARMA ENTER EXCLUSIVE LICENSE AGREEMENT FOR ONCE-WEEKLY ORAL GLP-1/GIP DUAL RECEPTOR AGONIST HRS-1596
    Source text: ID:nGNE9XCnQQ
    Further company coverage: [NOVOb.CO]

     ((Reuters.briefs@thomsonreuters.com;))

    Recent news on Novo Nordisk A/S

    See all news